BPC-157 vs Cartilax

BPC-157

BPC-157 is a synthetic 15-residue peptide whose sequence was taken from a larger protein reported in human gastric juice. That parent protein, named body protection compound, is described mainly in the papers of the group that reported it, and the peptide is known almost entirely through its own studies. Most published work comes from that single research group and is in rodents, covering models of tendon, ligament, muscle and bone injury, lesions of the stomach and intestine, and some nervous-system models. Human data are very limited, consisting of a few small reports rather than controlled trials. Independent replication outside the originating group is limited.

Cartilax

Cartilax corresponds to the tripeptide Ala-Glu-Asp, one of the short peptide bioregulators studied in Russian gerontology research. The published literature names it AED or Kartalax, and PubChem lists Cartalax among the synonyms of Ala-Glu-Asp; the spelling Cartilax appears in no study located. Most of the work is cell culture from one St Petersburg group, covering skin fibroblasts, kidney explants, thymocytes and mesenchymal stem cells. The cartilage reports are three papers from that same group, published in Russian with English abstracts.

How BPC-157 acts

No receptor for BPC-157 has been identified. Rodent and cell studies have reported changes in several signalling systems, most often the nitric oxide system, VEGF receptor 2 signalling in endothelial cells, and the FAK–paxillin pathway in cultured tendon fibroblasts. Other papers describe interactions with dopamine and serotonin systems in animal models. Several studies have also examined growth-factor and early-response gene expression in injured tissue. Because many of these findings come from a small number of laboratories, using different models, the mechanism is best regarded as unsettled rather than as a known pathway.

How Cartilax acts

Short peptides of this class are proposed by their authors to enter the cell and act on gene expression rather than on a receptor. For AED, cell-culture reports describe changes in transcripts and proteins tied to proliferation, apoptosis and matrix turnover, including SOX9, aggrecan, type II collagen and COMP in human mesenchymal stem cells during chondrogenic differentiation. No binding partner or receptor is identified in the papers located, and the epigenetic route remains a proposal of the originating group rather than a demonstrated pathway.

The records side by side

• Type: BPC-157, Pentadecapeptide; Cartilax, Synthetic tripeptide
• Length: BPC-157, 15 amino acids; Cartilax, 3 amino acids
• Molecular weight: BPC-157, 1419.5 g/mol; Cartilax, 333.29 g/mol
• Molecular formula: BPC-157, C62H98N16O22; Cartilax, C12H19N3O8

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.